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Introduction: Matrix metalloproteinases (MMPs) are important in tissue remodelling. Here we investigate the role
of collagenase-3 (MMP-13) in antibody-induced arthritis.
Methods: For this study we employed the K/BxN serum-induced arthritis model. Arthritis was induced in C57BL/6
wild type (WT) and MMP-13-deficient (MMP-13–/–) mice by intraperitoneal injection of 200 μl of K/BxN serum.
Arthritis was assessed by measuring the ankle swelling. During the course of the experiments, mice were sacrificed
every second day for histological examination of the ankle joints. Ankle sections were evaluated histologically for
infiltration of inflammatory cells, pannus tissue formation and bone/cartilage destruction. Semi-quantitative PCR was
used to determine MMP-13 expression levels in ankle joints of untreated and K/BxN serum-injected mice.
Results: This study shows that MMP-13 is a regulator of inflammation. We observed increased expression of
MMP-13 in ankle joints of WT mice during K/BxN serum-induced arthritis and both K/BxN serum-treated WT and
MMP-13–/– mice developed progressive arthritis with a similar onset. However, MMP-13–/– mice showed significantly
reduced disease over the whole arthritic period. Ankle joints of WT mice showed severe joint destruction with
extensive inflammation and erosion of cartilage and bone. In contrast, MMP-13–/– mice displayed significantly
decreased severity of arthritis (50% to 60%) as analyzed by clinical and histological scoring methods.
Conclusions: MMP-13 deficiency acts to suppress the local inflammatory responses. Therefore, MMP-13 has a role
in the pathogenesis of arthritis, suggesting MMP-13 is a potential therapeutic target.Introduction
There is a growing body of evidence implicating matrix
metalloproteinases (MMPs) as major players in nume-
rous disease conditions including atherosclerosis, tumor
invasion, ulcerative diseases and arthritic diseases [1-4].
Rheumatoid arthritis (RA) is a chronic arthritic disease
resulting in joint destruction and loss of function in the
joints. Articular cartilage degradation, characteristic of
RA, is believed to be mediated by the collagenase sub-
family of MMPs [5]. Collagenases cleave fibril collagens
at neutral pH and play an important role in matrix re-
modeling. Collagens are the major structural proteins of
all connective tissues. The most abundant collagens are
types I, II and III, called interstitial collagens. Type I col-
lagen is widely distributed, being produced in bone, skin,* Correspondence: harald.illges@fh-brs.de
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reproduction in any medium, provided the ortendons, and ligament, whereas type II collagen is
located almost exclusively in hyaline cartilage.
Collagenase-3/MMP-13 is the most recently identified
member of the collagenase subfamily, originally isolated
from breast carcinoma [6]. In addition to its expression
in breast tumors, MMP-13 mRNA exhibits a more re-
stricted pattern of expression within connective tissue,
and is usually found in articular cartilage [7], in bone [8]
and in chondrocytes in osteoarthritis (OA) [9-11]. More-
over, MMP-13 was found in the synovial tissue from
patients with OA or RA [12]. MMP-13 was found to de-
grade collagen types I, II and III and the cartilage pro-
teoglycan aggrecans [13]. Biochemical characterization
of MMP-13 revealed a broad spectrum of activities
against connective tissue components [14]. In light of
the preference of MMP-13 for collagen type II of hyaline
cartilage degrading this substrate more efficiently as
compared with MMP-1 and MMP-8 [14], one is tempted
to speculate that MMP-13 is a critical component of thetd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cartilage, thus highlighting this molecule as a potential
therapeutic target for treatment of cartilage destruction.
Indeed, Li and colleagues recently described the inhi-
bition of MMP-13 as a new hope for the treatment of
OA [15]. Pharmaceutical inhibition of MMP-13 resulted
in reduced arthritis in the collagen-induced arthritis and
severe combined immunodeficiency mouse coimplanta-
tion model, but not in the antibody-induced arthritis
model [16].
In this study we investigated the role on MMP-13 in the
K/BxN sera-transfer arthritis model. In the K/BxN model,
arthritis occurs spontaneously in those mice expressing
both the transgene-encoded KRN T-cell receptor and
the IAg7 major histocompatibility complex class II allele
[17,18]. These transgenic T cells are specific for a self-
peptide derived from the glycolytic enzyme glucose-6-
phosphate isomerase (GPI) and are able to break tolerance
in the B-cell compartment, resulting in the production of
autoantibodies to GPI [19-21]. Joint specificity is explained
by the deposition of the GPI onto the articular cartilage
surface, binding of anti-GPI antibodies to the surface
and subsequent complement-mediated inflammation [22].
Transfer of serum from the K/BxN mice into C57BL/6
mice resulted in the development of a transient arthritis in
the recipients. Here we show that MMP-13 expression is
increased in C57BL/6 mice during the course of the
K/BxN serum-induced arthritis and that mice deficient for
MMP-13 (MMP-13–/–) are protected from inflammation
and joint destruction.
Methods
Experimental animals
KRN T-cell receptor-transgenic mice on the C57BL/6
background were a kind gift from Dr D Mathis and Dr C
Benoist (Strasbourg, France) and were bred to NOD/Lt
(N) mice to generate K/BxN mice [17]. MMP-13–/– mice
on a pure C57BL/6 background were described previously
[23]. C57BL/6 wild-type (WT) mice were obtained from
Charles River Laboratories (Sulzfeld, Germany). All mice
were maintained and bred at the animal facility of the
University of Applied Sciences, Rheinbach. All mice were
sex and age-matched for experiments and were between 6
and 10 weeks of age. All experiments were approved by
the Nordrhein-Westfalen state authorities (Landesamt für
Natur und Umweltschutz) and complied with European
Community regulations (86/609/EEC) for the care and
use of laboratory animals.
Arthritic serum preparation and transfer into mice
Serum was separated from the blood obtained by bleeding
from the tail vein of arthritic K/BxN mice (12 to 18 weeks
old), pooled and frozen at –20°C until use. For inducing
arthritis in WT or MMP-13–/– mice, each mouse wasinjected intraperitoneally with 200 μl equivalent of serum
from arthritic K/BxN mice.
Assessment of antibody-induced arthritis by ankle
thickness and clinical index score
Development of arthritis in mice was assessed by cali-
per measurement (model number 33185; Hann &Kolb,
Stuttgart, Germany) of ankle thickness and by the clinical
index, a visual score based on the number of ankles
affected. Ankle thickness for each mouse was expressed in
millimeters. The error was expressed as the standard error
of the means. The ankle score was 0 if no ankle was
affected, and was 1 if one ankle was slightly affected. An
inflammation score of 0 was counted if no ankle was
affected; a score of 0.25 if an ankle showed reddening and
was less swollen; a score of 0.75 if reddening and a mode-
rately swollen ankle was observed; and a score of 1 if
an ankle showed reddening and was strongly swollen.
Histology was performed and evaluated in a blinded man-
ner as described elsewhere [24].
RNA extraction
Hind-paw ankle joints from WT mice were isolated at
days 0 (that is, control), 3, 8 and 14 after K/BxN serum
transfer. The ankle joints were trimmed of skin, muscle,
and excess bone around the articular joint and immedia-
tely frozen on dry ice. Total RNA was extracted using the
PeaqGold total RNA kit (PeaqLab, Erlangen, Germany),
according to the manufacturer’s instructions.
Standard reaction for MMP-13
cDNA products (2 μl) were applied for amplification with
10 units of Taq polymerase and corresponding buffer
(Qiagen GmbH, Hilden, Germany) in the presence of
15 mM MgCl2, 25 mM dNTP and 5 pmol sense and anti-
sense primers (MWG Eurofins, Ebersberg, Germany).
Murine ribosomal large protein P 0 (m36b4) transcript
levels served as a quantity and quality control. The reaction
was carried out in the PTC-200 system (MJ Research,
Biorad, Munich, Germany) with a first cycle of 2.5 minutes
at 95°C for complete denaturation, followed by 25 cycles of
denaturation (1 minute at 90°C), annealing (1 minute at
61°C for MMP-13 and 1 minute at 60°C for m36b4, re-
spectively) and synthesis (1 minute at 72°C). The condi-
tions were chosen so that the polymerase chain reaction
products were in the exponential phase of amplification.
Each set of reactions always included a no-sample nega-
tive control (water) and a positive control (knee joint of
control mouse).
Primer selection
The following primers were used: MMP-13, sense 5′-CC
TTCTGGTCTTCTGGCACAC-3′ and antisense 5′-GG
CTGGGTCACACTTCTCTG-3′; and m36b4, sense 5′-
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5′-CCG ACT CCT CCG ACT CTT C-3′.
Acquisition of gel images and quantitative analysis
Images of reverse transcriptase polymerase chain reaction
ethidium bromide-stained agarose gels were acquired with
PeqLab E-box (Metabion, Planegg, Germany) and quantifica-
tion of bands was performed using a Chemidoc (Biorad,
Munich, Germany). Band intensity was expressed as relative
absorbance units. The sample RNA to be determined and
m36b4 was calculated to normalize for initial variation in the
sample concentration and as a control for reaction efficiency.
Statistical analysis
Statistical significance was analyzed using Graphpad Prism
software, La Jolla, USA. Data are expressed as the mean ±
standard error of the means. Comparisons were per-
formed using the unpaired Student t test or by analysis of
variance. For comparison of histological data, the non-
parametric Mann–Whitney U test was used. Differences
were considered statistically significant when P <0.05.
Results
Quantification of MMP-13 mRNA expression in ankle
joints of wild-type mice
To determine whether the expression of MMP-13 was
upregulated during arthritis development, we examined
its expression in the joints by polymerase chain reactionMMP 13 
0
50
100
150
200
%
 F
o
ld
  I
n
cr
ea
se
Std =m36b4
A
B
Days After Seru
0 3 8
**
0 3
Days A
Figure 1 MMP-13 expression in joints during arthritis development. (
from hind paws of mice at days 0, 3, and 8 and 14 showing matrix metallopro
arthritogenic serum in control C57BL/6 mice. C, cDNA from RNA isolated from
transcript levels served as control for quality and quantity of tested RNA. (B) Q
**P <0.01.(Figure 1a). WT mice were injected intraperitoneally
with 200 μl arthritogenic K/BxN serum at day 0. Mice
were sacrificed and RNA was prepared from the joint
tissue, as explained in Methods, at various time points
post injection. Semi-quantitative polymerase chain reac-
tion analysis showed that MMP-13 expression increased
on day 3, and was highest on day 8 after arthritis induc-
tion. Expression on day 14 was reduced to levels seen on
day 0. The increase in MMP-13 expression correla-
ted positively with the increase in ankle measurement
(Figure 2) and histological scores (Figure 3) observed in
mice after arthritis induction.
MMP-13–/– mice show mild levels of K/BxN serum-induced
arthritis
To determine the role of MMP-13 during the develop-
ment of K/BxN sera-induced arthritis, MMP-13–/– mice
and the WT control mice were injected intraperitoneally
with 200 μl arthritogenic K/BxN serum and indicative
parameters of arthritis were compared in WT mice and
mutant mice over time. Arthritis was monitored every
2 days by measuring ankle thickness and clinical index.
The onset of arthritis occurred 2 days after injection of
sera in both WT control mice and MMP-13–/– mice.
The ankle thickness and clinical index increased to a
peak value between days 8 and 10, after which the
disease resolved until day 18 (Figure 2a,b). However, in
contrast to WT mice, MMP-13–/– mice showed reducedm Transfer
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Figure 2 Mice deficient for MMP-13 were protected from antibody-induced arthritis. Mice deficient for matrix metalloproteinase-13
(MMP-13–/–; n = 21) and wild-type mice (n = 20) were treated with 200 μl K/BxN sera, and arthritis was evaluated by measuring (A) the ankle
thickness and (B) the clinical index. There was a significant difference in ankle thickness and clinical index scores between the two groups. Values
represent the mean ± standard deviation of ankles/time points, which were compared using the Student t test. *P <0.05, **P <0.01. KO, knockout.
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nical index decreased by 1.4-fold (P <0.001) and 1.5-fold
(P <0.001) respectively when compared with the WT
mice. These findings suggest that MMP-13 has a significant
role in antibody-induced arthritis.
Decreased inflammation and joint destruction in
MMP-13–/– mice
Inflammation and joint destruction were assessed histo-
logically from ankle sections of mice sacrificed on days 0,
2, 6, 8 and 14. On day 8 post serum transfer, WT mice
showed proliferating inflamed synovial tissue (pannus)
expanded over the surface of the articular cartilage
(Figure 4c). At sites of contact of the pannus tissue with
the cartilage matrix and/or bone, degradation of the car-
tilage and erosion of the bone surface occurred, whereas
in MMP-13–/– mice there was no cartilage destruction or
pannus formation observed (Figure 4d). Histological2 4 6 8 14
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Figure 3 Arthritis scores of wild-type C57BL/6 and mice deficient for
of the synovial tissue by polymorphonuclear mononuclear leukocytes and ex
damage in mice was induced with K/BxN sera in wild-type mice and mice de
for synovial inflammation, cartilage and bone destruction were significantly lo
show the mean ± standard deviation. P values determined using the Mann–Wevaluation of synovial inflammation revealed increased
infiltration by polymorphonuclear and mononuclear leu-
kocytes, exudation of granulocytes, hyperplasia of the
synovial tissue (Figure 3a) and cartilage and bone destruc-
tion of joints in WT mice compared with MMP-13–/–
mice at days 4 and 8 post serum transfer (Figure 3b).
These observations indicate that MMP-13 promotes
antibody-induced joint inflammation and destruction.
Clinical severity of arthritis was higher in WT mice
compared with MMP-13–/– mice (day 8 (mean ± standard
deviation): inflammation score, 6 ± 0.5 in WT mice and
1.8 ± 0.5 in MMP-13–/– mice, P <0.05; destruction score,
1.5 ± 0.5 in WT mice and 0.6 ± 0.5 in MMP-13–/– mice,
P <0.0043) (Figure 3).
Discussion
The degradation of articular cartilage is a characteristic
of RA. Since MMPs are extremely efficient in cleaving2 4 6 8 14
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Figure 4 Representative histopathology of ankle joints from wild-type mice and mice deficient for MMP-13. (A), (B) Day 0 (before serum
transfer): notice the even and clear joint space (js) and smooth articular cartilage (ac). (C), (D) Day 8 (post serum transfer): (C) wild-type joints
display the fibrovascular synovial and periarticular proliferation (fp), erosion of ac, intra-articular exudates and osteolysis in severely affected joints
(arrows), whereas (D) joints of mice deficient for matrix metalloproteinase-13 (MMP-13) are nearly free of inflammation and the synovium retains
its relatively acellular composition (arrows). Images were taken at 40× and 100× magnification. KO, knockout.
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pathogenesis of RA. The collagenase MMP subfamily
members MMP-1 and MMP-13 have both been sug-
gested to play a role in this degradation. Multiple studies
have demonstrated a prominent role for MMP-13 in tis-
sue injury and repair. In addition, MMP-13 was recently
shown to have a higher activity than MMP-1 against
type II collagen [14], which is the major component of
articular cartilage. MMP-13 mRNA has been detected in
human articular cartilage [7] and synovial membranes
[12]. Moore and colleagues found induction of MMP-13
in RA synovial fibroblasts [25].
To understand better the role of MMP-13 in arthritis
development and progression we studied the role of
MMP-13 in the K/BxN serum-induced arthritis model.
We induced arthritis using the K/BxN serum in the
MMP-13–/– mice and in the control C57BL/6 mice. Both
the control C57BL/6 mice and the MMP-13–/– mice
developed arthritis within 2 days after K/BxN serum
transfer (Figure 2). However, as the disease progressed the
MMP-13–/– mice exhibited a significantly reduced disease
when compared with that observed in the C57BL/6 mice.
Further, the MMP13–/– mice showed a significant reduc-
tion in inflammation and in bone and cartilage destruction
when compared with the control C57BL/6 mice on days 4
and 8 post serum transfer (Figure 3). On analyzing the
expression of MMP-13 mRNA levels in the joints of the
C57BL/6 mice injected with K/BxN serum, we observed a
significant increase in the expression of MMP-13 on day 8
post serum transfer when the mice exhibited maximum
increase in ankle thickening (Figure 1). These resultsstrongly implicate MMP-13–/– as an important protease
in the pathology of antibody-induced arthritis in mice.
However, the mild pannus formation and cartilage de-
struction observed in the MMP-13–/– mice might be due
to compensation by other proteases such as cathepsin K,
which have been shown to be involved in joint destruction
in the collagen-induced arthritis model [26]. The data
presented in this study thus suggest, for the first time,
an important role for MMP-13 in the progression of
antibody-induced arthritis.
Our results correspond well to studies in other mouse
models that have implicated MMP-13 in development of
arthritis. Recently, Little and colleagues showed that
global knockout of MMP-13 could prevent articular carti-
lage erosion [27]. Jungel and colleagues found upon oral
application of a highly selective MMP-13 inhibitor that
arthritis was significantly decreased in the severe com-
bined immunodeficiency and collagen-induced arthritis
model, whereas no significant effects were seen in the
antibody-induced arthritis model [16]. Interestingly, when
Wang and colleagues induced OA by meniscal ligamen-
tous injury in MMP-13Col2ER mice, where MMP-13 was
specifically knocked out in the cartilage, they observed a
significant deceleration in OA progression that was ac-
companied by a reduced proteoglycan and chondrocyte
destruction when compared with OA observed in the con-
trol mice [28]. Their results show that a deficiency of
MMP-13 in chondrocytes is sufficient for protection
against OA. Using the K/BxN serum-transfer we show an
increase in expression of MMP-13 on day 8 post serum
transfer in the C57BL/6 mice. We also observed a
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day 8 post serum transfer in these mice, indicating a simi-
lar role for chondrocyte-specific MMP-13 in antibody-
induced arthritis.
In this study we tested the role of MMP-13 using
MMP13–/– mice in an antibody-induced arthritis model.
Our studies clearly show that deletion of MMP-13 atte-
nuates arthritis progression in mice. MMP-13 inhibition
may thus have potential for the treatment of arthritis
progression, and the K/BxN serum-induced arthritis mo-
del will serve as a useful tool to study the efficiency of
MMP-13 inhibitors in treating arthritis.
Conclusion
This study clearly shows that MMP-13 promotes inflamma-
tion and joint destruction in the K/BxN serum-induced
arthritis model. Our data demonstrate that MMP-13 is re-
quired for a sustained inflammatory response that occurs in
the effector phase of arthritis and suggest a role for MMP-
13 apart from cartilage destruction in modulating the in-
flammatory response. Drugs aiming to inhibit MMP-13
function might thus be potential candidates for RA therapy.
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